Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 versus LINCOMYCIN HCL.
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
600-900 mg IV every 8 hours, or 900 mg IV every 12 hours.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is 2.4–3.0 hours in adults with normal hepatic and renal function; prolonged in severe hepatic impairment (up to 8–10 hours) and in neonates (8–20 hours).
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Approximately 10% of administered dose excreted renally as active drug; significant biliary/fecal elimination (about 40% as active drug and metabolites) via enterohepatic circulation.
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic